About us

Our Mission

We exist to develop curative solutions that achieve total and faster healing for non-healing wounds and other complex inflammatory diseases with our four-in-one biologic drug, AUP-16.

Our Vision

Our goal is to create solid Phase 2 clinical efficacy data in diabetic foot ulcers and non-clinical proof-of-concept data in other inflammatory diseases by end of 2022, and to engage with strategic partners to ensure that this game changing technology benefits millions of patients.

Leadership Team

JUHA YRJÄNHEIKKI

CEO

LAURENT DÉCORY

COO

THOMAS WIRTH

CSO

HARITHA SAMARANAYAKE

CMO

MAIJA RUSI

Financial & Administrative Director

IGOR MIERAU

Director of CMC

SCIENTIFIC ADVISORY BOARD

BOARD OF DIRECTORS

Serial Entrepreneur, Board Professional and Biotech Business Advisor

Biotech Investor, Senior Executive and Board Professional

Learn more About this
life-changing
technology

Contact us